In this study, combined with available clinical information, we describe the mutation map and molecular mechanism of the main driver genes in HCC through gene exon sequencing and mutation data from public databases; in addition, we tailored a prognosis prediction model for TP53 wild-type HCC patients and screened out potential therapeutic drugs for high-risk patients. This evidence concerns the gene TP53 and hepatocellular carcinoma.